MARCH 10 - 14, 2024

2024 Annual SOT Meeting and ToxExpo

days
Hours
Minutes
Seconds

Booth

#1509

Presentation

March 12, 2023

Poster #104

March 14, 2023

BioIVT at the 63rd Annual SOT Meeting and ToxExpo

Numerous BioIVT experts, leaders and team members will be available at the 2024 Annual SOT Meeting & ToxExpo booth #1509 in Salt Lake City, UT. Dr. Brian Ogilvie, BioIVT VP of Scientific Consulting, will also be presenting "Carboxylesterases in Drug Metabolism: Challenges and Opportunities." and a collaborative poster entitled “Sinclair Nanopig: From Multi-Omics Characterization to Pharmacology and Toxicology Validation Underline Drug Metabolism and Immune System” featuring research conducted at BioIVT’s Kansas City lab will be presented by Yafei Chen from Altasciences.

We are excited to have the opportunity to share with you and other industry leaders how we can help accelerate your research. Meet with our team to learn more about how we can help you:

CONFERENCE SCHEDULE

9:00 am - 4:30 pm

ToxExpo Exhibits

Visit BioIVT at the 2024 SOT Conference, Booth 1509.

Talk to our business development professionals and scientific experts about our comprehensive portfolio of biospecimen products and ADME-Tox research services.

Click here to schedule a meeting with our team of experts at the BioIVT booth

1:30 PM - 2:30 PM

Carboxylesterases in Drug Metabolism: Challenges and Opportunities

Room: 155E
Speaker: Brian Ogilvie, PhD, VP of Scientific Consulting

Abstract: Carboxylesterases (CES) represent an important pathway of drug metabolism. However, the striking differences in terms of number of carboxylesterases and tissue distribution make interspecies extrapolation a challenge. Several factors affect biotransformation and efficacy of drugs that are metabolized by CES. CES-mediated clinical drug-drug interactions (DDI) should also be evaluated. The regulatory guidance recommends examining CES-mediated metabolism for drugs that do not undergo significant metabolism by CYP enzymes.

The presentation is a high-level overview of in vitro DDI and ADME studies required for drug development with a focus on study design and data interpretation, as well as red flags to look for in in vitro DDI study reports, including methods and conclusions drawn from the underlying data.

Our SOT Presence

Dr. Brian Ogilvie, Vice President, Scientific Consulting will be presenting "Carboxylesterases in Drug Metabolism: Challenges and Opportunities,” where he will discuss the current understanding of the role of carboxylesterases (CES) in drug metabolism, factors affecting the expression and activity of CES like tissue distribution and species differences, and potential for drug interactions.

Discover the Details